UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
In this issue of Blood, authors of 2 articles have compared busulfan with total body irradiation (TBI) in preparative regimens for hematopoietic transplantation as treatment of acute myeloid leukemia (AML). 1, 2 M yeloablative preparative regimens are designed to eradicate the leukemia and provide sufficient immunosuppression to prevent graft rejection. The optimal regimen for patients with AML is controversial. Cyclophosphamide (Cy) combined with either TBI 3 or busulfan (Bu) 4,5 have been widely used. A randomized study published in 1992 showed superior results with the Cy-TBI compared with Bu-Cy using the oral busulfan formulation available at that time. 6 Oral busulfan is erratically absorbed, resulting in broad variation in blood levels. Busulfan systemic exposure is related to toxicities, disease control, and treatment-related mortality. 7-9 An intravenous busulfan formulation has subsequently been developed, which provides more consistent pharmacokinetics and reliable dosing 10 ; it may also avoid first-pass hepatotoxicity related to oral dosing. Intravenous busulfan has largely replaced the oral formulation in preparative regimens for hematopoietic transplantation.
These 2 articles directly compare busulfan and TBI for hematopoietic transplantation as treatment of AML in the modern era. A total of 1483 patients were enrolled; most had AML. Cohorts were balanced for prognostic factors impacting outcome. For AML patients, 2-year survival was 57% with busulfan and 46% with TBI-based regimens; P 5 .003. The only concern of note was a higher incidence of hepatic venoocclusive disease for Bu (5%) than with TBI (1%). There were no differences in progression-free survival and graft-versus-host disease. The combination of busulfan and fludarabine has been studied as a potentially less toxic alternative to busulfan-cyclophosphamide.
11,12
The Bredeson study also compared patients receiving busulfan-fludarabine vs busulfan-cyclophosphamide; there was no difference in outcomes with these preparative regimens.
Together, these 2 studies indicate improved survival in patients receiving a preparative regimen using intravenous busulfan compared with TBI for myeloablative hematopoietic transplantation as treatment of AML. Ideally, this should be confirmed by a randomized controlled trial, but a similarly sized randomized trial is not feasible. The available data indicate that, compared with myeloablative TBI, a preparative regimen using intravenous busulfan is relatively safe and effective for treatment of AML, and thus it should be considered a standard of care for allogeneic hematopoietic transplantation in these patients. 
New specs for arteriovenous identity -----------------------------------------------------------------------------------------------------Edward M. Conway 1 1 UNIVERSITY OF BRITISH COLUMBIA
In this issue of Blood, Aranguren et al 1 provide new insights into the molecular mechanisms that determine the identity of human endothelial cells: ie, will they line arteries or veins? The findings have implications in our understanding of vascular disease and in the design of vascular-specific therapies and tissue engineering. E ndothelial cells lining arteries and veins arise from mesoderm-derived angioblasts in the embryo. 2 The common origin of these endothelial cell populations belies the fact that arteries and veins have distinct structural features, properties, and functions. The Greek anatomist Erasistratus is credited with being the first to distinguish these 2 vessel types during the third century BCE. Even though he believed that they carry air, his insights have spurred generations of scientists, including Galen (second century AD), Harvey (17th century AD), and, most recently, Aranguren et al, 1 to attempt to delineate the unique "signatures" of arteries and veins and how they evolve. What dictates whether an angioblast will emerge as an artery or vein? The complex molecular mechanisms underlying arteriovenous (AV) specification, particularly in the embryo, have been studied in many species. Although there are differences, all support the notion that AV specification is driven primarily by a cell-intrinsic program that initially occurs independent of blood flow.
3 Mesodermderived angioblasts that form the primitive vascular plexus are already fated to be either arterial or venous. 
